One-Fifth of 50,000 Malaysians suffering stroke annually due to atrial fibrillation
KUALA LUMPUR -- One-fifth of the 50,000 Malaysians suffered stroke each year due to atrial fibrillation (AF), an irregular heartbeat disorder.
AliveCor mobile ECG available in USA
AliveCor announced today that its mobile Heart Monitor for iPhone is now available by prescription to enable patients to record their heart rhythm anytime, anywhere. The Heart Monitor, which makes home cardiac assessment quick and easy, is the first FDA-cleared mobile device–based ECG monitor that is compatible with iPhone4 and 4S. The device will be demonstrated at Booth #S708 (Expo South) at the ACC.13 annual meeting of the American College of Cardiology March 9 through March 11 in San Francisco.
German AF Network celebrates 10 years
13th March 2013, ESC
Atrial fibrillation is not directly life-threatening. But it leads to severe complications such as stroke. In order to look scientifically into this widespread disease and to improve care, the AFNET was founded in 2003 and has since then been funded by the German Federal Ministry of Research and Education (BMBF) with 17 million Euros. AFNET consists of a network of 600 physicians and scientists. About 20 clinical trials, registries, and basic research projects have been performed so far.
Getting to the heart of atrial fibrillation
IF THE recent and sudden withdrawal of Tendai "The Beast" Mtawarira from the Springbok squad has had any benefits, it’s the attention it has drawn to a relatively common, and sometimes devastating, heart condition — one that could be a growing concern for other rugby forwards.
Apixaban Gets EU OK for Stroke Prevention in AF
22nd November 2012, MedPage Today
The European Commission, the European Union's equivalent to the FDA, has approved the use of apixaban (Eliquis) for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
New Anticoagulant Holds Promise for Stroke Prevention
16th November 2012, Zawya
Dubai, United Arab Emirates, 15 November 2012 -During the 3rd Annual Emirates Cardiac Society Congress that was recently held in Dubai, Bayer Healthcare announced the registration and availability in the UAE of Rivaroxaban, a new oral anticoagulant that potentially prevents strokes and overcomes the limitations of current treatments that have been prescribed since the 1950s.
Top heart rhythm specialist leads debate on treatment
15th November 2012, Cambridge News
A consultant cardiologist at Papworth Hospital is leading the way in discussing developments for people whose hearts have an irregular beat.
Fish Oil Won't Prevent Irregular Heartbeat After Cardiac Surgery: Study
7th November 2012, Newsday
A hoped-for effect of fish oil supplements in preventing an irregular heartbeat that often follows heart surgery did not materialize in a major new trial.
Rivaroxaban recommended for approval for pulmonary embolism in Europe
29th October 2012, Vascular News
The European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the approval of the oral anticoagulant rivaroxaban for the treatment of pulmonary embolism and prevention of recurrent pulmonary embolism and deep vein thrombosis.
Treatments can reduce stroke risk in patients
29th October 2012, The Times of India
Atrial fibrillation patients can reduce their risk of stroke by rhythm control treatments and by the use of antithrombotic therapies, according to experts.